6-O-benzylguanine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
6-O-benzylguanine
DrugBank Accession Number
DB11919
Background

6-O-benzylguanine has been used in trials studying the treatment of HIV Infection, Adult Gliosarcoma, Adult Glioblastoma, Stage I Adult Hodgkin Lymphoma, and Stage II Adult Hodgkin Lymphoma, among others.

Type
Small Molecule
Groups
Investigational
Structure
Thumb
Weight
Average: 241.2486
Monoisotopic: 241.096359999
Chemical Formula
C12H11N5O
Synonyms
  • O(6)-Benzylguanine
  • O6-benzylguanine
External IDs
  • NSC-637037

Pharmacology

Indication

Not Available

Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:
Machine Learning
Data Science
Drug Discovery
Accelerate your drug discovery research with our fully connected ADMET dataset
Learn more
Contraindications & Blackbox Warnings
Contraindications
Contraindications & Blackbox Warnings
With our commercial data, access important information on dangerous risks, contraindications, and adverse effects.
Learn more
Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Medicalerrors
Reduce medical errors
and improve treatment outcomes with our comprehensive & structured data on drug adverse effects.
Learn more
Reduce medical errors & improve treatment outcomes with our adverse effects data
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
1,2-BenzodiazepineThe therapeutic efficacy of Benzodiazepine can be decreased when used in combination with 6-O-benzylguanine.
AbametapirThe serum concentration of 6-O-benzylguanine can be increased when it is combined with Abametapir.
AbataceptThe metabolism of 6-O-benzylguanine can be increased when combined with Abatacept.
AbirateroneThe serum concentration of 6-O-benzylguanine can be increased when it is combined with Abiraterone.
AcebutololThe risk or severity of adverse effects can be increased when Acebutolol is combined with 6-O-benzylguanine.
AcenocoumarolThe metabolism of 6-O-benzylguanine can be decreased when combined with Acenocoumarol.
AcetaminophenThe metabolism of 6-O-benzylguanine can be decreased when combined with Acetaminophen.
AcetazolamideAcetazolamide may increase the excretion rate of 6-O-benzylguanine which could result in a lower serum level and potentially a reduction in efficacy.
AcyclovirThe metabolism of 6-O-benzylguanine can be decreased when combined with Acyclovir.
AdalimumabThe serum concentration of 6-O-benzylguanine can be decreased when it is combined with Adalimumab.
Interactions
Improve patient outcomes
Build effective decision support tools with the industry’s most comprehensive drug-drug interaction checker.
Learn more
Food Interactions
Not Available

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as hypoxanthines. These are compounds containing the purine derivative 1H-purin-6(9H)-one. Purine is a bicyclic aromatic compound made up of a pyrimidine ring fused to an imidazole ring.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Imidazopyrimidines
Sub Class
Purines and purine derivatives
Direct Parent
Hypoxanthines
Alternative Parents
Aminopyrimidines and derivatives / Alkyl aryl ethers / Benzene and substituted derivatives / Imidazoles / Heteroaromatic compounds / Azacyclic compounds / Primary amines / Organopnictogen compounds / Hydrocarbon derivatives
Substituents
Alkyl aryl ether / Amine / Aminopyrimidine / Aromatic heteropolycyclic compound / Azacycle / Azole / Benzenoid / Ether / Heteroaromatic compound / Hydrocarbon derivative
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
01KC87F8FE
CAS number
19916-73-5
InChI Key
KRWMERLEINMZFT-UHFFFAOYSA-N
InChI
InChI=1S/C12H11N5O/c13-12-16-10-9(14-7-15-10)11(17-12)18-6-8-4-2-1-3-5-8/h1-5,7H,6H2,(H3,13,14,15,16,17)
IUPAC Name
6-(benzyloxy)-9H-purin-2-amine
SMILES
NC1=NC(OCC2=CC=CC=C2)=C2N=CNC2=N1

References

General References
Not Available
PubChem Compound
4578
PubChem Substance
347828250
ChemSpider
4417
BindingDB
5491
ChEMBL
CHEMBL407874
ZINC
ZINC000005425464
PDBe Ligand
OBG
PDB Entries
3kzz

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedTreatmentMalignant Neoplasms of Eye, Brain and Other Parts of Central Nervous System1
2CompletedTreatmentAnaplastic Gliomas / Glioblastoma Multiforme (GBM)1
2CompletedTreatmentBrain and Central Nervous System Tumors2
2CompletedTreatmentColorectal, Cancer1
2CompletedTreatmentMalignant Melanoma of Skin1
2CompletedTreatmentMultiple Myeloma and Plasma Cell Neoplasm1
2CompletedTreatmentRecurrent Adult Brain Tumor1
2CompletedTreatmentSarcomas1
2TerminatedTreatmentAstrocytomas / Gliomas / Oligoastrocytoma / Oligodendrogliomas1
2TerminatedTreatmentBrain and Central Nervous System Tumors1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility2.63 mg/mLALOGPS
logP2.09ALOGPS
logP1.71ChemAxon
logS-2ALOGPS
pKa (Strongest Acidic)8.98ChemAxon
pKa (Strongest Basic)4.71ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area89.71 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity67.62 m3·mol-1ChemAxon
Polarizability24.63 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0006-9511000001-e6a03ce9bd4d7464a377

Enzymes

Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Roy SK, Korzekwa KR, Gonzalez FJ, Moschel RC, Dolan ME: Human liver oxidative metabolism of O6-benzylguanine. Biochem Pharmacol. 1995 Oct 26;50(9):1385-9. [Article]

Drug created on October 20, 2016 21:00 / Updated on June 12, 2020 16:53